AYTU BIOPHARMA, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AYTU BIOSCIENCE, INC. (also referred to as AYTU BIOPHARMA, INC.) on March 27, 2018, reporting an event that occurred on March 26, 2018. The company is incorporated in Delaware and is headquartered in Englewood, Colorado.
Key Financial Metrics
The filing reports the exercise of an over-allotment option related to a public offering that initially closed on March 6, 2018.
- Shares Sold: 2,000,000 shares of common stock.
- Gross Proceeds: $899,980 (prior to underwriting discounts and offering expenses).
- Net Proceeds: The filing text does not provide a clear value for net proceeds after deductions.
The filing does not provide data on revenue, profit, operating cash flow, margins, debt, or liquidity positions.
Material Changes
The primary material change is the increase in outstanding common stock and capital raised through the exercise of the underwriters' over-allotment option. This event follows the initial closing of the public offering on March 6, 2018.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific discussion of risks and contingencies beyond the standard disclosure of the capital raise event.
Key Facts for Investor Verification
- Verify the final net proceeds after deducting underwriting discounts and offering expenses.
- Confirm the total number of shares outstanding following the issuance of the 2,000,000 additional shares.
- Review the initial offering prospectus (closed March 6, 2018) to understand the full scope of the capital raise.